MarketPulse
N

$NVO

64 articles found
24 positive
16 negative
23 neutral
The Motley FoolThe Motley Fool··Geoffrey Seiler

Hims & Hers Surges 40% on Novo Nordisk Deal, But Valuation Concerns Linger

Hims & Hers surges 40% after Novo Nordisk partnership resolves litigation, enabling authorized distribution of Wegovy and Ozempic. Stock trades under 20x forward P/E.
NVOHIMSGLP-1 drugstelemedicine
BenzingaBenzinga··Vandana Singh

Roche's Breast Cancer Drug Falls Short in Pivotal Trial, Stock Drops 5%

Roche's giredestrant failed to meet primary endpoint in Phase 3 breast cancer trial, causing 5% stock decline. Company plans adjuvant trial readout in 2027.
LLYNVORHHBYclinical trial failurePhase 3 trial
BenzingaBenzinga··Vandana Singh

Hims & Hers Settles Novo Nordisk Patent Dispute, Inks GLP-1 Partnership

Hims & Hers and Novo Nordisk end legal battle, partnering to distribute weight-loss drugs via telehealth. Stock surges 48.67% despite mixed guidance.
NVOHIMSguidance missearnings beat
BenzingaBenzinga··Rishabh Mishra

Stock Futures Tumble as Oil Surges on Iran Tensions; Trump Dismisses Spike

U.S. stock futures tumbled as crude oil surged 13-15% amid Iran tensions. Hims & Hers soared 49% on Novo Nordisk settlement; UniQure gained 36% on FDA clarity.
SPYQQQQURENVOHIMS+3stock market declinecrude oil
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

GLP-1 Glory or Diversified Dividend? Novo Nordisk vs. Amgen in Weight Loss Race

Novo Nordisk leads GLP-1 market but faces Eli Lilly competition; Amgen's MariTide offers differentiated approach with less portfolio risk.
AMGNLLYNVOclinical trialsmarket share
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Masks Valuation Risks for Long-Term Investors

Eli Lilly's GLP-1 success masks valuation risks; P/E of 44 leaves little room for competitive pressure and patent cliff execution.
PFELLYNVOGLP-1 drugsgeneric competition
The Motley FoolThe Motley Fool··Motley Fool Youtube

Novo Nordisk Stock Looks Cheap, But Execution Risks Cloud Recovery Outlook

Novo Nordisk stock trades cheap but faces execution headwinds versus Eli Lilly's superior operational performance in the booming GLP-1 market.
LLYNVOweight loss drugspharmaceutical competition
BenzingaBenzinga··Vandana Singh

Pfizer's Weight-Loss Drug Wins China Approval, Intensifying GLP-1 Competition

Pfizer wins NMPA approval for weight-loss drug ecnoglutide in China, achieving 15.4% average weight loss in trials, intensifying competition as Novo Nordisk's Wegovy faces patent expiry.
PFELLYNVOclinical trialweight-loss drug
BenzingaBenzinga··Vandana Singh

Roche's Obesity Drug Falls Short of GLP-1 Rivals in Phase 2 Results

Roche's obesity drug petrelintide achieved 10.7% weight loss in Phase 2 trials but significantly trails GLP-1 rivals Novo Nordisk and Eli Lilly, triggering sharp stock declines.
LLYNVORHHBYclinical trial resultsweight loss
The Motley FoolThe Motley Fool··Motley Fool Youtube

Novo Nordisk's Obesity Drug Underperforms Rival Zepbound in Late-Stage Trial

Novo Nordisk's Kagrama showed weaker weight-loss results than Eli Lilly's Zepbound in 84-week trial, pressuring obesity growth forecasts.
LLYNVOclinical trialweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Drug Market Poised to Triple to $202B by 2033 Amid Obesity Surge

Global GLP-1 receptor agonist market projected to grow from $70B in 2025 to $202B by 2033 at 12.78% annual rate, driven by obesity and diabetes prevalence.
LLYSNYNVOAZNIVBIYclinical trialsmarket growth
BenzingaBenzinga··Erica Kollmann

China Tech and Emerging Markets Hit Oversold Levels, Signaling Potential Rebound

China tech stocks and emerging market ETFs hit oversold extremes with depressed RSI readings, signaling potential rebound if risk sentiment improves.
BABANVOJDSEKWEB+4emerging marketse-commerce
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Market Set to Nearly Triple to $137B by 2030 as Drug Class Expands Beyond Diabetes

GLP-1 receptor agonist market projected to surge from $51.9B in 2024 to $137.4B by 2030, driven by obesity prevalence and expanded therapeutic applications.
AMGNPFELLYNVORHHBY+1weight lossdiabetes treatment
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Masks Valuation Risks; Analysts Eye Cheaper Alternatives

Eli Lilly trades at premium 44 P/E despite GLP-1 concentration risks. Novo Nordisk and Pfizer offer higher yields and lower valuations.
PFELLYNVOvaluationbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Novo Nordisk Expands Irish Plant, Elects Employee Board Representatives

Novo Nordisk elects four employee board representatives and invests €400+ million expanding Irish GLP-1 manufacturing capacity, signaling confidence in sustained demand.
NVOmanufacturing expansioncapital investment
GlobeNewswire Inc.GlobeNewswire Inc.··Novo Nordisk

Novo Nordisk Invests €432M in Irish Plant to Boost GLP-1 Drug Output

Novo Nordisk invests €432M in Irish manufacturing expansion to boost oral GLP-1 drug production capacity, targeting completion by 2028.
NVOmanufacturing expansioninvestment
BenzingaBenzinga··Nabaparna Bhattacharya

Large-Cap Bloodbath: Novo Nordisk, First Solar Lead $2T Selloff

Ten large-cap stocks plunged last week, led by First Solar's 18.6% drop on weak guidance and Novo Nordisk's 6.6% decline over pricing concerns.
NUDCIKKRKKRSKKRT+8Q4 resultslarge-cap losers
GlobeNewswire Inc.GlobeNewswire Inc.··Patentvest

Patent Strength, Not Clinical Data, to Drive GLP-1 Market Leadership

Patent strength, not clinical efficacy, will drive GLP-1 market leadership as clinical outcomes converge. Companies with robust IP portfolios may capture disproportionate market share despite comparable results.
PFELLYNVORHHBYAZN+2GLP-1 drugsoral small-molecule
The Motley FoolThe Motley Fool··Rich Smith

Hims & Hers Faces Growth Deceleration as GLP-1 Market Dynamics Shift

Hims & Hers stock plunged 70% as GLP-1 market competition intensifies and growth slows. Despite challenges, company projects $2.8B 2026 revenue from diversified services.
LLYNVOHIMSearnings reportGLP-1 drugs
The Motley FoolThe Motley Fool··Adria Cimino

Eli Lilly Expands Obesity Drug Lead With Clinical Win and Product Innovation

Eli Lilly strengthens obesity drug dominance as competitor's treatment fails trials and Lilly launches new monthly-dose Zepbound pen, commanding 60% market share.
PFELLYNVOVKTXclinical trialsGLP-1 drugs